Associated Papers
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
39484452 (PubMed )
Supplement: media-2.zip › Extended_Data_Tables › Extended_Data_Table_1.xlsx › KRAS_GOF_DMS_Screen
Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target.
Vande Voorde J et al.
Nature Metabolism, 2023
37580540 (PubMed )
Supplement: 42255_2023_857_MOESM10_ESM.xlsx › Extended_data_5A
Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas.
Szpechcinski A et al.
Cancers, 2022
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
Adib E et al.
Genome Medicine, 2022
35428358 (PubMed )
Supplement: 13073_2022_1041_MOESM2_ESM.xlsx › S17_TCGA_AJ_TMB
MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis.
Lu D et al.
Cancers, 2022
35326531 (PubMed )
Supplement: cancers-14-01378-s001.zip › Supplementary_Table_S1_-_TCGA_clinicopathological_info.xlsx › TCGA_Clinicopathological_info
Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation.
Li Y et al.
Computational and Structural Biotechnology Journal, 2022
35284050 (PubMed )
Supplement: mmc1.docx
YTHDF1 Promotes Cyclin B1 Translation through m6A Modulation and Contributes to the Poor Prognosis of Lung Adenocarcinoma with KRAS/TP53 Co-Mutation.
Lou X et al.
Cells, 2021
34359836 (PubMed )
Supplement: cells-10-01669-s001.zip › cells-1216862-supplementary.xlsx › table_S1
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
33226070 (PubMed )
Supplement: btaa972_supplementary_data.zip › RAS_Manuscript_RMarkdown.tar.gz › RAS_Manuscript1.Revised › RAS_Variants_Scores.xlsx › Sheet1
Mutation Profile of Thymic Carcinoma and Thymic Neuroendocrine Tumor by Targeted Next-generation Sequencing.
Sakane T et al.
Clinical Lung Cancer, 2021
A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations.
Demuth C et al.
Oncotarget, 2018
Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.
Winther-Larsen A et al.
British Journal of Cancer, 2017
Frequent GNAS and KRAS mutations in pyloric gland adenoma of the stomach and duodenum.
Matsubara A et al.
The Journal of Pathology, 2013
Select a paper to view details